Clinical Trials

201411010

A phase 1/2 study of ALT-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab

201505024

An Open-Label, Multicenter, Phase I/Ib trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in patients with Relapsed or Refractory B-Cell Non-Hodgkin s Lymphoma and…

201608007

A Randomized Double-Blind Phase III Study Of Ibrutinib During And Following Autologous Stem Cell Transplantation Versus Placebo In Patients with Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype Phase III Principal…

201611137

Phase I Trial of Duvelisib (IPI-145) in Combination with Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas Phase I Principal Investigator Mehta-Shah, Neha Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201612005

A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma Phase I/II Principal Investigator Bartlett, Nancy Disease Site Lymphoid Leukemia; Non-Hodgkin’s Lymphoma Learn more…

201612068

Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) Phase III…

201612158

Lymphoma SPORE: LS1293: Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients with Cancer

201704108

A Pilot Trial of Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients with DLBCL Phase I Principal Investigator Ghobadi, Armin Disease Site Bone Marrow Transplant; Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201709117

A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas Phase I Principal Investigator Ratner, Lee Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201709185

ILyAD (Indolent Lymphoma And Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D (cholecalciferol) on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated…

201709201

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma Phase II Principal Investigator Kahl, Brad Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201710050

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission Phase III…

201710114

A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL) Phase I Principal Investigator Mehta-Shah, Neha Disease Site Non-Hodgkin’s Lymphoma Learn more about this…

201801026

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Phase II Principal Investigator Mehta-Shah, Neha Disease Site Non-Hodgkin’s Lymphoma Learn…

201804151

Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients with Follicular Lymphoma

201807106

A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Phase I/II Principal Investigator Kahl, Brad Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201810016

A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia Phase I/II Principal Investigator Bartlett, Nancy Disease Site Chronic Lymphocytic Leukemia (CLL); Lymphoid Leukemia Learn…

201811110

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma Phase I/II Principal Investigator Mehta-Shah, Neha Disease Site Hodgkin’s Lymphoma Learn more…

201812049

A Multi-Cohort Phase 1b Clinical Trial of Rituximab in Combination with Immunotherapy in Untreated and Previously Treated Follicular Lymphoma Phase I Principal Investigator Mehta-Shah, Neha Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at:…

201902041

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) Phase III Principal Investigator Bartlett, Nancy…

201902045

A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) Phase III Principal Investigator Kahl, Brad Disease Site…

201903187

A Phase 1, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282,Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R…

201904114

TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma Phase II Principal…

201905026

Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY) Phase N/A Principal Investigator Haroutounian, Simon Disease Site Breast; Hodgkin’s Lymphoma; Non-Hodgkin’s Lymphoma

201907002

Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age Phase II Principal Investigator Kahl, Brad Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at:…

201907085

A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a Car T Cell Treatment Targeting CD19 and CD22 and Consolidation With Anti PD-1 Antibody in Patients with Relapsed or…

201907116

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma Phase II Principal Investigator Bartlett, Nancy Disease Site Hodgkin’s Lymphoma Learn…

201908038

A Phase III, Randomized Study of Nivolumab (OPDIVO) Plus AVD or Brentuximab Vedotin (ADCETRIS) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Phase III Principal Investigator Bartlett,…

201908145

Randomized phase II/III study of venetoclax (ABT 199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double-expressing lymphomas

201911028

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients < or…

201912027

Phase I-II Trial of Venetoclax in Combination with R-ICE (V-RICE) Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Phase I/II Principal Investigator Cashen, Amanda Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

202001014

A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia Phase I Principal Investigator Ghobadi, Armin Disease…

202001157

A MULTICENTER, OPEN-LABEL, PHASE I STUDY TO EVALUATE THE SAFETY, EFFICACY,TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF RO7082859 AS A SINGLE AGENT AND IN COMBINATION WITH OBINUTUZUMAB ADMINISTERED AFTER A FIXED, SINGLE DOSE PRE-TREATMENT OF,OBINUTUZUMAB…

202003073

SGN35-31 – A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Phase III…

202005165

Phase II Trial with Safety Lead-in of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Phase II Principal Investigator Cashen, Amanda Disease Site Non-Hodgkin’s Lymphoma Learn more about this study…

202007154

A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) Phase I Principal Investigator Ratner, Lee Disease Site Lymphoid Leukemia; Non-Hodgkin’s Lymphoma Learn more about this study at:…